Home Cart Sign in  
Chemical Structure| 27200-12-0 Chemical Structure| 27200-12-0

Structure of Dihydromyricetin
CAS No.: 27200-12-0

Chemical Structure| 27200-12-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Dihydromyricetin (DHM), a natural flavonoid compound, has functions like anti-alcohol effects, anti-oxidation, anti-thrombosis, and anti-inflammatory and so on. It could reduce the effect alcohol has on GABA receptors in the brain.

Synonyms: Ampelopsin; Ampeloptin; Ampelopsin, Ampeloptin, DHM, Dihydromyricetin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Dihydromyricetin

CAS No. :27200-12-0
Formula : C15H12O8
M.W : 320.25
SMILES Code : O=C1[C@H](O)[C@@H](C2=CC(O)=C(O)C(O)=C2)OC3=CC(O)=CC(O)=C13
Synonyms :
Ampelopsin; Ampeloptin; Ampelopsin, Ampeloptin, DHM, Dihydromyricetin
MDL No. :MFCD00189451
InChI Key :KJXSIXMJHKAJOD-LSDHHAIUSA-N
Pubchem ID :161557

Safety of Dihydromyricetin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
A549R cells 5 μmol/L To evaluate the effect of dihydromyricetin on the chemosensitivity of A549R cells, results showed that dihydromyricetin significantly enhanced DDP-induced cell proliferation retardation and apoptosis. PMC10354416
PC9R cells 5 μmol/L To evaluate the effect of dihydromyricetin on the chemosensitivity of PC9R cells, results showed that dihydromyricetin significantly enhanced DDP-induced cell proliferation retardation and apoptosis. PMC10354416
HK-2 cells 50, 100, 200 μM 24 or 48 hours To investigate the inhibitory effect of dihydromyricetin on TGF-β1-induced miR-34a upregulation, results showed that dihydromyricetin significantly inhibited miR-34a upregulation and restored Klotho expression. PMC6520492
H4 neuroglioma cells 10 μM 16 hours Reduced α-synuclein aggregation and increased expression of LAMP-1 and LAMP-2A PMC6570948

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NOD-SCID mice Tumor xenograft model Subcutaneous injection 100 mg/kg, twice daily Twice daily, for 2 to 3 months To evaluate the inhibitory effect of dihydromyricetin on tumor growth, results showed that dihydromyricetin significantly inhibited tumor growth and enhanced the chemotherapeutic effect of DDP. PMC10354416
Mice Unilateral ureteral obstruction (UUO) model and Adriamycin nephropathy model Intragastric administration 100 mg/kg Once daily for three weeks To investigate the inhibitory effect of dihydromyricetin on renal fibrosis, results showed that dihydromyricetin significantly inhibited miR-34a upregulation, restored Klotho expression, and alleviated renal fibrosis. PMC6520492
Mice BAC-α-syn-GFP transgenic mice Intraperitoneal injection 4-40 mg/kg 4 hours Activated CMA pathways, reduced α-synuclein aggregation, and inhibited neuroinflammation PMC6570948
C57BL/6 mice Social isolation-induced anxiety model Oral 10 mg/kg/day Once daily for two weeks DHM treatment ameliorates social isolation-induced anxiety behaviors, reduces neuroinflammation, and restores the number and morphology of microglia in the hippocampus. PMC8724741

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03606694 Type 2 Diabetes Mellitus Phase 2 Not yet recruiting September 30, 2020 Mexico ... More >> Instituto de Terapeútica Experimental y Clínica. Centro Universitario de Ciencias de la Salud. Universidad de Guadalajara Guadalajara, Jalisco, Mexico, 44340 Less <<
NCT05623501 Alcohol-Related Disorders PHASE1 NOT_YET_RECRUITING 2025-12-31 University of Southern Califor... More >>nia, Los Angeles, California, 90089, United States Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.12mL

0.62mL

0.31mL

15.61mL

3.12mL

1.56mL

31.23mL

6.25mL

3.12mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories